/
In vitro & in vivo diagnostic substances company · E9 · FY ends Dec · Revenue $9M · 66.70% margin
$9.45
$0.04 (-0.42%)
Live · 05:23 PM
Margins and capital returns are both well above average: 66.70% operating margin, ROIC at 19.25%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 5.6%, steady but not accelerating.
At 64x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
64.3x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9M
▲ +5.6% YoY
Net Income (TTM)
$6M
▲ +169.9% YoY
Op. Margin
66.70%
▲ +42.3pp YoY
ROIC
19.25%
▲ +9.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$7M
▼ -423.9% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$12M
3Y CAGR: -28.4%
Continue Research
At a P/E of 64.3, Anbio Biotechnology (NNNN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Anbio Biotechnology scores 43/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Anbio Biotechnology scores 43 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 66.7% operating margin and a 19.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NNNN's valuation and scores 43/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.